Work

The interactome of soluble amyloid‐β across the Alzheimer's disease continuum

Year: 2025

Type: article

Abstract: Background In Alzheimer's disease (AD), amyloid β (Aβ) aggregates, ranging from soluble Aβ oligomers to insoluble Aβ plaques. During Aβ aggregation, in vitro and in silico screening has shown that aggregation‐prone regions (APRs) appear as an optimal binding site for protein‐protein interactions. Interacting partners that define disease pathways provide potential insight into the cellular environment and protein interactions present during pathological Aβ aggregation. Using mass spectrometry, several proteins beyond Aβ have been discovered in AD pathogenesis. However, there is currently limited knowledge about proteins interacting with soluble Aβ in human brain tissue. Method This study aimed to systematically assess which proteins interact with soluble Aβ in human cortex across the AD continuum (i.e. pathologically‐definite symptomatic AD, asymptomatic AD and non‐AD controls) through affinity purification‐mass spectrometry with a Aβ‐specific binding condition using two Aβ antibodies (4G8: Aβ 17‐24 and 6E10: Aβ 1‐17 ) and a non‐specific binding condition (magnetic beads‐bound proteins). For differential expression, Paired T tests were performed to detect proteins significantly more abundant in Aβ 17‐24 and Aβ 1‐17 binding conditions respectively, considered as the ‘’Aβ interactome’’. Co‐expression network analysis was performed to assess which proteins correlated with neuropathological staging. Proteins derived were then assessed for diagnostic group differences to detect early mediators of AD pathogenesis. Result The combined Aβ 17‐24 and Aβ 1‐17 interactome consisted out of 129 proteins, including APOE and the glial fibrillary acidic protein and vimentin, which were significantly more abundant in Aβ‐IPs versus beads. Co‐expression analysis revealed a protein module which was significantly negatively correlated with Aβ phase severity. Diagnostic group comparison indicated that proteins involved in cytoskeletal modelling (septins), clathrin‐mediated endocytosis, chaperone function, and Rho GTPase activity were already reduced in the interactome of early stage AD cases. In silico and in vitro validation confirmed the existence of C‐terminal Aβ APR homology in 40% of the mass‐spectrometry derived Aβ interactome candidates (including PCSK1, HS105 and FN3K). Conclusion Interactions of Aβ with proteins involved in septins, clathrin‐mediated endocytosis, and chaperone functions are diminished in AD, even in asymptomatic individuals. This observation suggests that the impaired physiological protein‐binding function of soluble Aβ might represent an early pathogenic event in the development of AD.

Source: Alzheimer s & Dementia

DOI: 10.1002/alz70855_100163